Holen Sie sich die Stockscreener-App
177.88
2.25%
3.92
Handel nachbörslich:
179.41
1.53
+0.86%
Schlusskurs vom Vortag:
$173.96
Offen:
$174.73
24-Stunden-Volumen:
1.78M
Relative Volume:
0.92
Marktkapitalisierung:
$30.19B
Einnahmen:
$16.30B
Nettoeinkommen (Verlust:
$1.36B
KGV:
22.64
EPS:
7.8573
Netto-Cashflow:
$2.05B
1W Leistung:
+9.86%
1M Leistung:
-12.18%
6M Leistung:
-3.37%
1J Leistung:
-3.10%
1-Tages-Spanne:
$173.32
$178.28
1-Wochen-Bereich:
$163.04
$179.25
52-Wochen-Spanne:
$134.65
$247.04
Iqvia Holdings Inc Stock (IQV) Company Profile
Firmenname
Iqvia Holdings Inc
Sektor
Branche
Telefon
919-998-2000
Adresse
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IQV
Iqvia Holdings Inc
|
177.88 | 29.52B | 16.30B | 1.36B | 2.05B | 7.8573 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-11-03 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-10-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-09 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-04-25 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-02-03 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Stephens | Overweight |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-13 | Eingeleitet | BTIG Research | Buy |
| 2023-11-02 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-03-17 | Eingeleitet | Truist | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-11-17 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-15 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-16 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-03-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2020-07-07 | Eingeleitet | Stephens | Equal-Weight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Hochstufung | CFRA | Sell → Hold |
| 2019-11-14 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-06-21 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-05-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-18 | Hochstufung | Jefferies | Hold → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-10-02 | Bestätigt | Robert W. Baird | Outperform |
| 2018-07-25 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-07-25 | Bestätigt | Stifel | Buy |
| 2018-07-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-04-13 | Hochstufung | Goldman | Neutral → Buy |
| 2018-03-07 | Hochstufung | SunTrust | Hold → Buy |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Iqvia Holdings Inc Aktie (IQV) Neueste Nachrichten
Jim Cramer on IQVIA: "I Like the Business Very Much, I Just Don't Know Whether This Is the Right Stock to Play It" - Finviz
Jim Cramer on IQVIA: “I Like the Business Very Much, I Just Don’t Know Whether This Is the Right Stock to Play It” - Yahoo Finance
Is IQVIA (IQV) Offering An Opportunity After Recent Share Price Declines? - Yahoo Finance
11 Analysts Assess IQVIA Holdings: What You Need To Know - Benzinga
IQVIA Rose 7% This Week. Here’s Where the Stock Could Head in 2026 - TIKR.com
IQVIA Holdings (IQV): RBC Capital Initiates Coverage with "Outpe - GuruFocus
IQVIA Seen Benefiting From Clinical Trial Rebound Through 2026 on AI Strength, RBC Says - marketscreener.com
IQVIA Holdings Inc (IQV)'s Winning Formula: Financial Metrics an - GuruFocus
Strive Asset Management LLC Buys Shares of 91,856 IQVIA Holdings Inc. $IQV - MarketBeat
Assessing IQVIA Holdings (IQV) Valuation After Analyst Revisions And AI Disruption Concerns - simplywall.st
IQVIA Holdings Inc. $IQV Shares Bought by Elo Mutual Pension Insurance Co - MarketBeat
RBC Capital initiates IQVIA Holdings stock at Outperform on trial activity outlook - Investing.com Australia
IQV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference - 01net
IQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference - 01net
IQVIA Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Analysts at Mizuho Remain Bullish on IQVIA (IQV) Following Q4 Results - Yahoo Finance
IQVIA Holdings, Inc. (IQV) Stock Analysis: A 32% Potential Upside In The Healthcare Sector - DirectorsTalk Interviews
IQVIA Holdings Inc. $IQV Holdings Decreased by Laurel Wealth Advisors LLC - MarketBeat
Real World Evidence Solutions Market Is Going to Boom Rapidly | - openPR.com
IQVIA Holdings Inc. (NYSE:IQV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
IQVIA Acquires Charles River Assets for $145 Million: Here’s the Street’s Scenario for 70% Upside - TIKR.com
TD Asset Management Inc Grows Stock Holdings in IQVIA Holdings Inc. $IQV - MarketBeat
Handelsbanken Fonder AB Sells 52,327 Shares of IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA HOLDINGS INC. ($IQV) CEO 2025 Pay Revealed - Quiver Quantitative
IQVIA Holdings Hits Day High with Strong 5.39% Intraday Surge - Markets Mojo
Keystone Investors PTE Ltd. Has $27.78 Million Holdings in IQVIA Holdings Inc. $IQV - MarketBeat
Erste Asset Management GmbH Trims Stock Position in IQVIA Holdings Inc. $IQV - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 17,121 Shares of IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA Holdings: Still Exceeding Expectations As A Stealth Compounder (NYSE:IQV) - Seeking Alpha
IQVIA Releases its 2025 Sustainability Report - 01net
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
11 Most Undervalued AI Stocks to Buy Now - Insider Monkey
Primecap Management Co. CA Has $89.11 Million Stock Holdings in IQVIA Holdings Inc. $IQV - MarketBeat
Artisan Partners Limited Partnership Raises Position in IQVIA Holdings Inc. $IQV - MarketBeat
Charles River Laboratories to divest a number of assets to IQVIA and GI Partners - Business Weekly
Is IQVIA Holdings Inc. (IQV) a Buy Post Earnings? - Finviz
IQVIA Holdings (IQV) Rallied on Waning Concerns Over Biotech Funding and Clinical Activity - Insider Monkey
IQVIA to acquire Charles River drug discovery assets - Yahoo Finance
3 Reasons to Sell IQV and 1 Stock to Buy Instead - Finviz
IQVIA Acquisition Expands Drug Discovery Role And Highlights Valuation Gap - Yahoo Finance
IQVIA to acquire drug discovery assets from Charles River Labs By Investing.com - Investing.com Australia
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Activist investor prompts sale of Charles River CDMO business, U.S. and European sites - The Business Journals
IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE - marketscreener.com
IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities - 01net
Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans - Benzinga
Did AI‑Driven Obesity Research Wins and Strong 2025 Results Just Shift IQVIA's (IQV) Investment Narrative? - simplywall.st
IQVIA to acquire drug discovery assets from Charles River Labs - Investing.com
Charles River raises annual profit view as it sells underperforming assets - marketscreener.com
Iqvia signs agreement to acquire drug discovery assets from Charles River Laboratories, expanding end-to-end drug discovery capabilities - marketscreener.com
Finanzdaten der Iqvia Holdings Inc-Aktie (IQV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.21%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):